Why Aegerion Pharmaceuticals (AEGR) Stock Is Down Today

NEW YORK (TheStreet) -- Aegerion Pharmaceuticals  (AEGR) fell Tuesday after the company announced the pricing of its offering of $300 million aggregate principal amount of 2% convertible senior notes due 2019.

The offering includes an option for initial purchasers to buy up to an additional $45 million aggregate principal amount of notes to cover overallotments. The conversion rate for the notes will start at 24.2866 shares of Aegerion common stock per $1,000 principal amount of notes, or approximately $41.175 per share. This represents a 35% premium to the stock's closing price of $30.50 on Monday.

The stock was down 1.44% to $30.06 at 10:47 a.m. More than 2.1 million shares had changed hands, compared to the average volume of 984,766.

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

AEGR Chart AEGR data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

5 Stocks Insiders Love Right Now

7 Stocks Under $10 Making Big Up Moves

5 Stocks Under $10 Set to Soar

Wall Street Loses Gains After Fed's Unsurprising June Call

Stocks Turn Lower After Yellen Expresses Confidence in U.S. Economy